News

Prismic is developing novel non-addictive prescription drugs with unique safety profiles with the goal of addressing the opioid crisis based on formulations utilizing micro-palmitoylethanolamide’s (“PEA”) “entourage” effect on

Under an exclusive worldwide license agreement, Fulcrum will develop and commercialize losmapimod, a potential disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD). Fulcrum is planning to advance losmapimod into

Keytruda is an anti-PD-1 therapy, while Inlyta is a tyrosine kinase inhibitor. Keytruda will help enhance the ability of the body’s immune system to detect and combat tumor

Approximately 20% of patients with TNBC have tumors that highly overexpress EGFR. No targeted therapy is approved for EGFR-overexpressing TNBC. The multicenter, dose-expansion, Phase 2a trial (AVID100-01; NCT03094169)

Solifenacin Succinate Tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Overactive bladder (OAB) is

NMOSD is a rare, life-threatening autoimmune disease affecting the central nervous system. “The Breakthrough Therapy Designation for inebilizumab is based on results from the largest monotherapy study ever

Phyton Biotech is the world’s leading manufacturer of paclitaxel active pharmaceutical ingredient (API), utilizing its prorprietary PCF technology process. Under the strategic partnership with AqVida, Phyton Biotech will

Both firms have announced that top-line results from a phase 3 study assessing tanezumab 2.5mg and 5mg. Tanezumab is an investigational monoclonal antibody, which works by selectively targeting,

Under the terms of the agreement, CASI has obtained global rights to TSK011010 for an upfront payment of 5 million euros and an equity investment of 2 million